Looks like Angiochem isn't dead yet.....

https://twitter.com/DDNewsOnline/status/1024657331399798784

Angiochem receives $7.5 million in Series C financing

"Proceeds to support ongoing development of ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer

(Montreal – August 1, 2018) - Angiochem Inc. (“Angiochem”) announced today that it has secured a $7.5 million Series C financing to pursue its development plan.

Angiochem is currently developing ANG1005 for the treatment of leptomeningeal carcinomatosis from breast cancer, for which there are no approved therapeutic treatment options currently available. Angiochem’s Phase 3 clinical trial for ANG1005 is expected to start later this year.  “This is a significant development for Angiochem. With this latest financing, the company is on track to further develop ANG1005. This compound has already delivered promising results and now, we are gearing up for a pivotal Phase 3 trial that will hopefully lead to a long awaited therapeutic solution for patients with breast cancer who suffer from brain metastases and leptomeningeal carcinomatosis,” said John Huss, Executive Chairman of Angiochem. “This is an important, unmet medical need.”"